GlassScriptPhysician profile
Leon S Maratchi
NPI 1063685964
$49,556.26
in general payments reported to CMS, 2019-2025
33 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,475 · 2020: $5,103 · 2021: $6,532 · 2022: $19K · 2023: $7,983 · 2024: $1,462 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,800 · Food and Beverage: $4,869 · Travel and Lodging: $438 · Education: $28.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,800.00 |
| Food and Beverage | $4,869.13 |
| Travel and Lodging | $437.81 |
| Education | $28.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43,824.31 | 2019-2025 | |
| Janssen Biotech, INC. | $929.38 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $673.98 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $475.93 | 2019-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $378.62 | 2019-2025 | Entyvio |
| Celgene Corporation | $359.69 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $322.15 | 2023-2025 | Omvoh, Mounjaro |
| Qol Medical, LLC | $308.24 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $296.67 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $278.73 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $171.18 | 2019-2025 | Clenpiq, Rebyota |
| Celltrion USA INC. | $151.54 | 2023-2025 | Vegzelma, Yuflyma |
| Regeneron Healthcare Solutions, INC. | $147.03 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $144.68 | 2022-2025 | Ibsrela |
| Shionogi INC | $122.60 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $119.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $98.98 | 2019-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $95.50 | 2019-2024 | Linzess |
| Pfizer INC. | $71.71 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $70.85 | 2023 | Stelara |
| Gilead Sciences, INC. | $69.86 | 2019-2025 | |
| Redhill Biopharma INC. | $57.93 | 2021-2023 | Talicia |
| Daiichi Sankyo INC. | $55.17 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $55.15 | 2023-2024 | |
| Allergan, INC. | $51.44 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $50.78 | 2024-2025 | Iqirvo |
| Medtronic, INC. | $44.10 | 2023 | Endoflip |
| Evoke Pharma, INC. | $32.13 | 2024-2025 | |
| Boston Scientific Corporation | $23.54 | 2025 | Axonics |
| Alfasigma USA, INC. | $21.40 | 2020 | |
| Nestle Healthcare Nutrition INC. | $21.26 | 2021 | |
| Ucb, INC. | $17.48 | 2019 | |
| Merck Sharp & Dohme LLC | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Maratchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.